Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2018

View Archived Issues

Kalytera terminates preclinical programs for synthetic endocannabinoid compounds in bone disease

Phase I results for CPI-613 in combination with high-dose cytarabine and mitoxantrone in AML

Presentations describe discovery, structure, mechanism and activity of AZD-4573

XNW-1011 demonstrates improved in vivo efficacy compared to ibrutinib

FDA accepts for review ALKS-5461 NDA for adjunctive treatment of major depressive disorder

Kineta and Genentech collaborate on the development of nAChR antagonists

Adocia initiates first-in-human trial of BC Pram Ins in patients with type 1 diabetes

Phase III study in Africa evaluates new combination treatment for visceral leishmaniasis

First-in-human study of ATX-GD-59 in patients with Graves' disease meets primary endpoint

Novel biomarkers identified for primary graft dysfunction after lung transplantation

New phase II trial investigates tislelizumab in relapsed-refractory mature T- and NK-cell lymphomas

Preclinical results presented for CD19-4-1BBL, a CD19-targeting antibody fusion protein

Bristol-Myers Squibb and Janssen collaborate on FXIa inhibitors

FDA clears IND for first-in-human trial of CAB-ROR2-ADC

LTP Technology allows enhanced liver targeting of tenofovir prodrugs

NeurOp initiates phase I trial of NP-10679

Mutabilis patents novel beta-lactamase inhibitors

Asana BioSciences divulges new P2X3 and/or P2X2/3 receptor antagonists

Basilea licenses derazantinib from ArQule

G1 Therapeutics initiates phase Ib/II study of G1T38 with Tagrisso in NSCLC

Advent enters exclusive negotiations to acquire Sanofi's European generics business

ImmuPharma reports topline results of pivotal Lupuzor trial in lupus

Roche identifies new gamma-secretase inhibitors

New muscarinic M1 receptor PAMs presented by The Vanderbilt University

Gilead presents new compounds for HIV infection

Apellis reports interim data from phase Ib PADDOCK study of APL-2 in PNH

FDA approves Opdivo + Yervoy for first-line treatment of intermediate- and poor-risk RCC

METRIC study of glembatumumab vedotin fails to meet primary endpoint

FDA grants breakthrough therapy designation to Hemlibra for hemophilia A without inhibitors

FDA designates tegavivint an orphan drug for desmoid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...